Two novel Co(II) complexes with two different Schiff bases: inhibiting growth of human skin cancer cells

Abstract

Using two flexible Schiff bases, H₂L₁ and H₂L₂, two new cobalt II (Co(II))-coordination compounds, namely, Py₃CoL₁ (1) and Py₃CoL₂ (2) (Py=pyridine, L₁=3,5-ClC₆H₂(O)C=NC₆H₃(O)-4-NO₂, L₂=3,5-BrC₆H₂(O)C=NC₆H₃(O)-4-NO₂) have been synthesized under solvothermal conditions. Single crystal X-ray structural analysis revealed that compounds 1 and 2 are both six-coordinate in a distorted octahedral geometry, and the 1D chain structure was formed by the π…π and C-H…O interactions or C-H…Cl interaction. The in vitro antitumor activities of 1, 2 and their corresponding organic ligands Py, L₁, and L₂ were studied and evaluated, in which three human skin cancer cell lines (A-431, HT-144 and SK-MEL-30) were used in the screening tests.

Schiff bases; Coordination compound; Antitumor activity

Introduction

Cancer is a proliferation disorder disease with apoptosis obstacles (¹,²). It strikes more than one-third of the world's population and causes over 20% of all deaths (³). Standard cancer treatment protocols include surgery, radiotherapy and chemotherapy (⁴). Unfortunately, chemotherapy is not effective in treating cancers associated with innate resistance to apoptosis and/or acquired resistance to drugs during treatment. Discovery of novel effective anticancer medicines is therefore of great importance (⁵).

Cobalt complexes with Schiff bases have received considerable attention in the fields of coordination chemistry and biological chemistry (⁶). Cobalt functions as the active site of hydrolytic enzymes, such as carboxypeptidase and carbonic anhydrase where it is in a hard-donor coordination environment of nitrogen and oxygen (⁷). Cobalt has been recognized as an important cofactor in biological molecules, either as a structural template in protein folding or as a Lewis acid catalyst that can readily adopt four-, five-, or six-coordination (⁷,⁸). The cobalt (Co) complexes with the Schiff bases derived from salicylaldehyde and its analogues have been extensively studied (⁹). In this work, two new Co(II) complexes, Py₃CoL₁ (¹) and Py₃CoL₂ (2) (Figure 1) (Py=pyridine, L₁=3,5-ClC₆H₂(O)C=NC₆H₃(O)-4-NO₂, L₂=3,5-BrC₆H₂(O)C=NC₆H₃(O)-4-NO₂), were solvothermally prepared by employment of two different base ligands and their antitumor activities were then evaluated.

Figure 1.
Scheme representation of compounds Py₃CoL₁ (1) and Py₃CoL₂ (2).

Material and Methods

Apparatus and materials

All starting materials and reagents used in this research were obtained commercially and used without further purification. Element analyses (C, H, and N) were determined with an elemental Vario EL III analyzer (Elementar, Germany). Single-crystal X-ray diffraction data for compounds 1 and 2 were recorded on Mercury CCD diffractometer (Bruker Optics, Germany). The melting points were taken on a XT-4 micro melting apparatus (Ledon, China), and the thermometer was uncorrected. Three human skin cancer cell lines (A-431, HT-144 and SK-MEL-30) were purchased from Sigma-Aldrich (USA).

Synthesis and characterization of compounds 1 and 2

A mixture of CoCl₂ (1.0 mmol, 0.130 g), and 3,5-dichlorosalicylaldehyde-2-amino-4-nitrophenol Shiff base (H₂L₁, 1.0 mmol, 0.327 g) were mixed in 25 mL methanol. After heating and dissolving in air, 10 mL methanol solution of CoCl₂ (50 mM) was added to the reaction flask. Most of the solvent was removed by rotary evaporators after 2 h of reaction. Then, pyridine was dropped to dissolve, and the solution continued to reflux for 2 h. The solution was cooled down to room temperature and filtered and the brown crystals of solution 1 were obtained. Analytical characteristics found for compound 1 (C₂₈H₂₁Cl₂CoN₅O₄) were: C, 54.18; H, 3.39; N, 11.30%. Calculate: C, 54.13; H, 3.41; N, 11.27%.

The synthesis method for compound 2 was similar to that of compound 1. Analytical characteristics found for compound 2 (C₂₈H₂₁Br₂CoN₅O₄) were: C, 47.40; H, 3.00; N, 9.85%. Calculate: C, 47.35; H, 2.98; N, 9.86%.

Crystal structure determination

Structural measurement was performed on the computer-controlled Mercury CCD diffractometer with graphite-monochromated Mo-Kα radiation (λ=0.71073 Å) at T=293 (²) K. Absorption correction was made using the SADABS (Bruker AXS Inc., USA) program. The structure was solved using the direct method and refined by full-matrix least-squares methods on F² using the SHELXS-97 program package (¹⁰). Crystallographic data and structural refinements for compounds 1 and 2 are summarized in Table 1.

Table 1.
Crystal data and structure refinement for Py₃CoL₁ (1) and Py₃CoL₂ (2).

	1	2
Formula	C28H21Cl2CoN5O4	C28H21Br2CoN5O4
Mr	621.33	710.25
Temperature/K	296 (2)	296 (2)
Crystal system	Triclinic	Triclinic
Space group	Pī	Pī
a/Å	8.8780 (13)	8.8470 (7)
b/Å	9.0856 (13)	9.1799 (8)
c/Å	17.703 (3)	18.0141 (15)
α/°	104.445 (2)	104.335 (1)
β/°	92.184 (2)	91.368 (1)
γ/°	99.919 (2)	99.064 (1)
V/Å3	1357.2 (3)	1396.7 (2)
Z	2	2
Dcalc/g·cm-3	1.520	1.689
μ(Mo Kα)/mm-1	0.874	3.519
θ range/°	2.35 to 28.03	2.32 to 25.99
Reflections collected	17,238	15,294
No. unique data [R(int)]	6459 [0.0262]	5441 [0.0232]
No. data with I ≥ 2σ(I)	4,846	4,122
R 1	0.0391	0.0328
ωR2(all data)	0.1058	0.0836
CCDC	960,791	960,795

CCDC numbers for compounds 1 and 2 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: [phone]; E-mail: [e-mail])

Antitumor activity

Stock solutions of 1, 2 and their corresponding organic ligands Py, L₁ and L₂ were prepared in DMSO and kept at -20°C. Appropriate dilutions of the compounds were freshly prepared just prior to the assays. Final concentrations of DMSO did not interfere with the cell growth.

Three human skin cancer cell lines (A-431, HT-144 and SK-MEL-30) grown as monolayer were routinely maintained in RPMI-1640 medium supplemented with 5% heat inactivated FBS, 2 mM glutamine and antibiotics (penicillin 100 U/mL, streptomycin 100 μg/mL), at 37°C in a humidified atmosphere containing 5% CO₂. Exponentially growing cells were obtained by plating 1.5×10⁵ cells/mL for A-431 and HT-144 and 0.75×10⁴ cells/mL for SK-MEL-30, followed by 24 h of incubation. The effect of the vehicle solvent (DMSO) on the growth of these cell lines was evaluated in all the experiments by exposing untreated control cells to the maximum concentration (0.5%) of DMSO used in each assay.

Results and Discussion

Molecular structure

The crystal structure determined by single-crystal X-ray diffraction showed that 1 and 2 both crystallize in the triclinic system, space group Pī. The asymmetric unit comprises one Co(II) atom, three pyridine molecules, one 3,5-dichlorosalicylaldehyde-2-amino-4-nitrophenol or 3,5-dibromosalicylaldehyde-2-amino-4-nitrophenol Shiff base, respectively.

As shown in Figures 2A and 3A, the central Co1 atom is six-coordinate in a distorted octahedral geometry and is surrounded by two oxygen atoms (O1 and O2) and one amino nitrogen atom (N1) from the ligand, and three nitrogen atoms (N3, N4, and N5) from three different pyridines. The axes positions were occupied by two nitrogen atoms (N1 and N4 for 1; N1 and N5 for 2) from Shiff base ligand (3,5-dichlorosalicylaldehyde-2-amino-4-nitrophenol for 1; 3,5-dibromosalicylaldehyde-2-amino-4-nitrophenol for 2) and one pyridine molecule, respectively. The angle of N1-Co1-N4 and N1-Co1-N5 is 173.94° and 173.92°, respectively, which obviously deviates from linear angle 180°. The equatorial positions were occupied by four atoms (O1, O2, N3 and N5 for 1; O1, O2, N3 and N4 for 2). The bond lengths and bond angles between the four atoms in the equatorial plane and the center of the Co1 atom are also different [for 1, Co1-O1=2.0116 (14) Å, Co1-O2=2.0609 (15) Å, Co1-N3=2.2210 (18) Å, Co1-N5=2.2029 (18) Å, ∠O1-Co1-N3=93.85 (6)°, ∠O2-Co1-N3=92.48 (7)°, ∠O1-Co1-N5=86.86 (6)°, ∠O2-Co1-N5=88.57 (7)°; for 2, Co1-O1=2.0157 (19) Å, Co1-O2=2.0610 (19) Å, Co1-N3=2.217 (2) Å, Co1-N4=2.207 (2) Å, ∠O1-Co1-N3=93.81 (8)°, ∠O2-Co1-N3=92.92 (9)°, ∠O1-Co1-N4=86.66 (8)°, ∠O2-Co1-N4=88.39 (9)°], so the central Co1 atom is six-coordinate in a distorted octahedral geometry in the complexes 1 and 2.

Figure 2.
A, Molecular structure of compound 1 (Py₃CoL₁); B, packing of compound 1 in unit cell; C, 1D infinite chain structure of compound 1 was formed by the π…π and C-H…O interactions; D, 1D infinite chain structure of compound 1 was formed by the C-H…Cl interactions.

Figure 3.
A, Molecular structure of compound 2 (Py₃CoL₂); B, packing of compound 2 in unit cell; C, 1D ribbon-like structure of compound 2 was formed by the C-H…O hydrogen bonding interaction, D, 1D chain-like structure of compound 2 was formed by the C-H…Br interaction.

The packing of the compounds 1 and 2 in unit cell is shown in Figures 2B and 3B, respectively. Moreover, for 1, the π…π and C-H…O interactions were observed between adjacent molecules, which led to the formation of an interesting 1D chain structure (Figure 2C). The C-H…Cl interaction in an adjacent molecule also resulted in the formation of a 1D chain structure (Figure 2D); for 2, the C-H…O Hydrogen bonding interactions [H17…O4ⁱ 2.5939 (29) Å, ∠C17-H17…O4ⁱ 171.995 (232)°, i: 1+x, y, z; H25…O3ⁱⁱ 2.5571 (30) Å, ∠C25-H25…O3ⁱⁱ 136.210 (306)°, ii: 2-x, 2-y, -z; H23…O3ⁱⁱⁱ 2.5816 (35) Å, ∠C23-H23…O3ⁱⁱⁱ 129.866 (196)°, iii: 1-x, 2-y, -z;] were observed between adjacent molecules, which led to the formation of an interesting 1D ribbon-like structure (Figure 3C). The C-H…Br interaction [H21…Br1ⁱ 2.8754 (4) Å, ∠C21-H21…Br1ⁱ 149.139 (227)^o, i: x, 1+y, z] in an adjacent molecule also resulted in the formation of a 1D chain-like structure (Figure 3D).

Antitumor activity

The tumor cell growth inhibition activities of 1, 2 and their corresponding organic ligands Py, L₁ and L₂ were assessed in vitro on 3 human skin cancer cell lines (A-431, HT-144, and SK-MEL-30) after continuous exposure for 48 h. The results were compared to the antiproliferative effects of the reference control doxorubicin. All compounds were dissolved in DMSO at 1 mg/mL immediately before use and diluted just before addition to the cell culture.

Data are reported as means±SE of 3 independent experiments performed in duplicate (Table 2). The antiproliferative activity of the test compounds against each of the title tumor cell lines may be arranged in a descending order according to the measured concentration required to inhibit tumor cell proliferation by 50% (IC₅₀ μ/M). From the results, we can see that compounds 1 and 2 showed significant growth inhibition activity on the 3 tumor cell lines (IC₅₀=11.3∼19.8 μ/M), compared to their corresponding organic ligands Py, L₁ and L₂ (IC₅₀=90.8∼120.5 μ/M).

Table 2.
Antiproliferative activity IC₅₀ (μM) of Py₃CoL₁ (1) and Py₃CoL₂ (2) and their corresponding organic ligands Py, L₁ and L_2.

Compounds	IC50 (μM)
	A-431	HT-144	SK-MEL-30
Py	114.5±6.2	120.5±6.1	117.5±4.9
L1	93.2±7.1	94.9±6.9	98.8±7.0
L2	90.8±3.5	112.6±5.3	111.7±5.9
1	11.3±2.7	17.8±3.1	19.8±4.8
2	16.3±1.8	17.1±2.1	17.4±2.6
Doxorubicin*	0.158±0.067	0.141±0.061	0.180±0.041

• Data are reported as means±SE of 3 independent experiments performed in duplicates. IC₅₀: Drug concentration required to inhibit tumor cell proliferation by 50% after continuous exposure of 48 h. *Doxorubicin was used as positive control.

In conclusion, we successfully obtained two new Co(II)-coordination compounds (1 and 2) by employing two different flexible Schiff base ligands. From the biological activity investigation, we observed that the antitumor activity of compounds 1 and 2 advanced greatly when organic ligands pyridine and Schiff bases were in coordination with Co ion. However, additional studies are needed to define the mechanism underlying this antitumor activity and evaluate the drug efficacy in vivo.

References

• ¹
  Borisova NE, Reshetova MD, Ustynyuk YA. Metal-free methods in the synthesis of macrocyclic Schiff bases. Chem Rev 2007; 107: 46–79, doi: 10.1021/cr0683616.
  » https://doi.org/10.1021/cr0683616
• ²
  Guo XK, Sun HP, Shen S, Sun Y, Xie FL, Tao L, et al. Synthesis and evaluation of gambogic acid derivatives as antitumor agents. Part III. Chem Biodivers 2013; 10: 73–85, doi: 10.1002/cbdv.201200126.
  » https://doi.org/10.1002/cbdv.201200126
• ³
  Götz M, Wortmann P, Schmid S, Hugel T. A multicolor single-molecule FRET approach to study protein dynamics and interactions simultaneously. Methods Enzymol 2016; 581: 487–516, doi: 10.1016/bs.mie.2016.08.024.
  » https://doi.org/10.1016/bs.mie.2016.08.024
• ⁴
  Chen Y, Bian Y, Sun Y, Kang C, Yu S, Fu T. Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. Peer J 2016; 4: e2140, doi: 10.7717/peerj.2140.
  » https://doi.org/10.7717/peerj.2140
• ⁵
  Diedrich B, Rigbolt KT, Röring M, Herr R, Kaeser-Pebernard S, Gretzmeier C, et al. Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. EMBO J 2017; 36: 646–663, doi: 10.15252/embj.201694732.
  » https://doi.org/10.15252/embj.201694732
• ⁶
  Han R, Sun Y, Kang C, Sun H, Wei W. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. J Drug Target 2017; 25: 140–148, doi: 10.1080/1061186X.2016.1207649.
  » https://doi.org/10.1080/1061186X.2016.1207649
• ⁷
  Al-Harbi SA, Bashandy MS, Al-Saidi HM, Emara AA, Mousa TA. Synthesis, spectroscopic properties, molecular docking, anti-colon cancer and anti-microbial studies of some novel metal complexes for 2-amino-4-phenylthiazole derivative. Spectrochim Acta A Mol Biomol Spectrosc. 2015; 145: 425–439, doi: 10.1016/j.saa.2015.03.054.
  » https://doi.org/10.1016/j.saa.2015.03.054
• ⁸
  Ryckbosch SM, Wender PA, Pande VS. Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes. Nat Commun 2017; 8: 6, doi: 10.1038/s41467-016-0015-8.
  » https://doi.org/10.1038/s41467-016-0015-8
• ⁹
  Greiss F, Kriegel F, Braun D. Probing the cooperativity of binding networks with high-throughput thermophoresis. Anal Chem 2017; 89: 2592–2597, doi: 10.1021/acs.analchem.6b04861.
  » https://doi.org/10.1021/acs.analchem.6b04861
• ¹⁰
  Sheldrick GM. SHELXL-97. Program for crystal structure solution and refinement. Götingen: University of Götingen; 1997.

Publication Dates

• Publication in this collection
  2017

History

• Received
  8 Feb 2017
• Accepted
  27 Apr 2017